Microdosing for weight maintenance

Microdosing is not about driving weight loss.

It’s about providing a gentle, consistent signal that helps reduce rebound appetite and “food noise” once weight loss is complete.

Why low-dose continuation is used clinically

  • Starter-level doses (such as 0.25 mg weekly GLP-1 injections) are widely used to maintain tolerance and physiological signalling
  • Continued exposure, even at lower intensity, is associated with better weight stability than complete discontinuation
  • Lower doses are often better tolerated long term

Our service applies this principle using a carefully controlled, low-frequency oral format.

Dosing format (maintenance only)

Typical schedule:

  • 0.2 mg sublingual tablet
  • Twice weekly — Monday & Friday
  • At least 3 months’ supply per order (30 tablets)

Optional variation (not routinely recommended):
Some individuals may use up to three times weekly (Mon/Wed/Fri).
This would last approximately 10 weeks from a 30-tablet supply.
⚠️ We do not recommend exceeding three doses per week within a microdosing maintenance approach.

Sublingual Delivery

Sublingual explainer

Why Sublingual?

Why sublingual?

Sublingual tablets dissolve under the tongue, rather than being swallowed or injected.


Practical advantages

  • No injections
  • Discreet and travel-friendly
  • Simple routine that suits long-term use
  • No refrigeration or cold storage

About absorption

Liraglutide is a peptide medicine. Peptide absorption via the mouth is complex and formulation-dependent.

We do not claim sublingual delivery is superior to licensed products.

Instead, it may offer a practical, user-friendly alternative for people already familiar with GLP-1 treatment, where the goal is maintenance rather than intensity.

Weight Maintenance Method Pricing

Start Your Eat Less Journey

£225

3 Months’ Supply

Safety & Screening

Important safety information
This service screens out anyone who:

  • Is seeking active weight loss
  • Is pregnant or breastfeeding
  • Has a history of pancreatitis, MEN2, medullary thyroid cancer
  • Has a current or past eating disorder
  • Cannot provide photo ID or required images

Treatment may be declined at clinician discretion.